SCHEMBL6741280

SCHEMBL6741280

C[C@@H](C[CH]C(=O)N[C@H]1CCN(S(=O)(=O)c2ccc(OC3CCNCC3)c(Cl)c2)C1)C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 8/20 0.55
NPC1 O15118 2/20 0.42
POLB P06746 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
RAB9A P51151 1/20 0.42
ATM Q13315 1/20 0.42
HTR2C P28335 4/20 0.41
KCNH2 Q12809 3/20 0.41
HTR2A P28223 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 1/20 0.40
HTR1A P08908 1/20 0.39
CYP2D6 P10635 1/20 0.39
DRD2 P14416 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1F P30939 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6744780 0.91 UTS2R (0.61) UTS2RHTR2CHTR1ACYP2D6DRD2
SCHEMBL6742625 0.91 UTS2R (0.61) UTS2RHTR2CHTR1ACYP2D6DRD2
SCHEMBL6741196 0.90 UTS2R (0.48) UTS2RNPC1POLBSMN1; SMN2RAB9A
SCHEMBL6744733 0.87 UTS2R (0.44) UTS2RPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL6741880 0.87 UTS2R (0.44) UTS2RPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL6739732 0.86 UTS2R (0.46) UTS2RNPC1POLBSMN1; SMN2MEN1
SCHEMBL6839472 0.84 UTS2R (0.44) UTS2RNPC1POLBSMN1; SMN2HTR2C
SCHEMBL6093947 0.84 SMN1; SMN2 (0.44) UTS2RPOLBSMN1; SMN2HTR2CMEN1
SCHEMBL6741282 0.84 UTS2R (0.58) UTS2RNPC1POLBSMN1; SMN2RAB9A
SCHEMBL6741630 0.82 UTS2R (0.46) UTS2RSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders SMITHKLINE BEECHAM CORPORATION 2004-08-05 US claimed
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders SMITHKLINE BEECHAM CORPORATION 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders UTS2R, PLAUR, SERPINE1 UTS2R 1/4885NPC1 4334/4885POLB 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.